An electrochemical biosensor for simultaneous detection of breast cancer clinically related microRNAs based on a gold nanoparticles/graphene quantum dots/graphene oxide film

Pothipor, Chammari; Jakmunee, Jaroon; Bamrungsap, Suwussa

doi:10.1039/d1an00436k

Cited by 87 publications

(36 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[31] developed a 12‐miRNA panel, which yielded an AUC of 0.94, a sensitivity of 0.84, a specificity of 0.91, a PPV of 0.90, and an NPV of 0.85, in 216 patients with breast cancer and 214 normal controls. Several other lncRNAs (AUC 0.74–0.95) [32–34], microRNA (AUC 0.86–0.99) [35–37], and DNA methylation panels (AUC 0.58–0.98) [38] also showed high diagnostic accuracy, which is corresponded to the accuracy of serum SEMA4C levels in diagnosing breast cancer. However, these tests are not always readily available and lack clinical application in low‐resource settings.…”

Section: Discussionmentioning

confidence: 99%

Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study

Wang

Qiao

Yang

et al. 2021

Cancer Communications

View full text Add to dashboard Cite

Background To date, there is no approved blood‐based biomarker for breast cancer detection. Herein, we aimed to assess semaphorin 4C (SEMA4C), a pivotal protein involved in breast cancer progression, as a serum diagnostic biomarker. Methods We included 6,213 consecutive inpatients from Tongji Hospital, Qilu Hospital, and Hubei Cancer Hospital. Training cohort and two validation cohorts were introduced for diagnostic exploration and validation. A pan‐cancer cohort was used to independently explore the diagnostic potential of SEMA4C among solid tumors. Breast cancer patients who underwent mass excision prior to modified radical mastectomy were also analyzed. We hypothesized that increased pre‐treatment serum SEMA4C levels, measured using optimized in‐house enzyme‐linked immunosorbent assay kits, could detect breast cancer. The endpoints were diagnostic performance, including area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. Post‐surgery pathological diagnosis was the reference standard and breast cancer staging followed the TNM classification. There was no restriction on disease stage for eligibilities. Results We included 2667 inpatients with breast lesions, 2378 patients with other solid tumors, and 1168 healthy participants. Specifically, 118 patients with breast cancer were diagnosed with stage 0 (5.71%), 620 with stage I (30.00%), 966 with stage II (46.73%), 217 with stage III (10.50%), and 8 with stage IV (0.39%). Patients with breast cancer had significantly higher serum SEMA4C levels than benign breast tumor patients and normal controls (P < 0.001). Elevated serum SEMA4C levels had AUC of 0.920 (95% confidence interval [CI]: 0.900–0.941) and 0.932 (95%CI: 0.911–0.953) for breast cancer detection in the two validation cohorts. The AUCs for detecting early‐stage breast cancer (n = 366) and ductal carcinoma in situ (n = 85) were 0.931 (95%CI: 0.916–0.946) and 0.879 (95%CI: 0.832–0.925), respectively. Serum SEMA4C levels significantly decreased after surgery, and the reduction was more striking after modified radical mastectomy, compared with mass excision (P < 0.001). The positive rate of enhanced serum SEMA4C levels was 84.77% for breast cancer and below 20.75% for the other 14 solid tumors. Conclusions Serum SEMA4C demonstrated promising potential as a candidate biomarker for breast cancer diagnosis. However, validation in prospective settings and by other study groups is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study

Wang

Qiao

Yang

et al. 2021

Cancer Communications

View full text Add to dashboard Cite

show abstract

“…Therefore, the assaying of multiple miRNA markers from one sample is necessary for accurate detection and higher specificity. 45 Only handful of research has been reported thus far on the multiplexed and simultaneous detection of only two or three miRNAs using biosensors for early BC detection [46][47][48][49][50][51][52][53][54][55][56][57][58][59][60] from the body fluids. To the best of our knowledge, there is no systematic review conducted on the electrochemical biosensors for multiplexed DCIS miRNAs detection.…”

Section: Dcis Stages Grades and Incidencementioning

confidence: 99%

“…The developed biosensor reveals simultaneous sensing with sensitivity values of 3.5, 2.9 and 1.8 μA/pM for the three miRNAs and also demonstrated selective recovery from human serum samples. 48 The significance of the design of the reported biosensor is that it is simple and without any labelling molecules, less time for the fabrication and detection, low cost, and reduced assay procedure.…”

Section: Ecs Sensors Plus 2022 1 021602mentioning

confidence: 99%

See 1 more Smart Citation

Review—Systematic Review on Electrochemical Biosensing of Breast Cancer miRNAs to Develop Alternative DCIS Diagnostic Tool

Guruswami

Ponpandian

et al. 2022

ECS Sens. Plus

View full text Add to dashboard Cite

Till date, no systematic review is conducted on electrochemical biosensing of multiplexed breast cancer miRNAs to identify their suitability as an alternative diagnostic tool for ductal carcinoma in-situ (DCIS). Original articles published in English from PUBMED, Science Direct, Scopus, MEDLINE, Cochrane Library, National Centre for Biotechnology Information, and Google scholar during Jan 2012– Feb 2022 were searched using set inclusion criteria. The Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 2020 guidelines was followed to report this review. Methodological quality of the included studies was evaluated using Risk of Bias (ROB) assessment criteria. Out of 1973 screened articles, 17 studies were eligible and included in this review wherein, 1 study (5.88%) involving generic neutravidin modified nanolabel probe using biotintylated molecular beacons immobilized metal nanoparticles prepared using one pot assay to detect miRNAs 21 and 141 had low ROB and 16 studies (94.12%) had medium ROB. Medium ROB of majority of the included studies reveals its limited evidence to conclude its suitability for diagnosing DCIS using miRNAs. High quality studies with inter assays and validation are extensively needed for the development of diagnostic tool for DCIS via miRNAs.

show abstract

“…Besides, investigations have also been conducted using probes anchored by different redox species in CD-based electrochemical sensors for the simultaneous sensing of multiple nucleic acid biomarkers. A recent study by Pothipor et al revealed that the designed three-screen-printed carbon electrode (3SPCE) array sensor based on the modification of gold nanoparticles (AuNPs)/GQDs/GO was able to detect miRNA-21, miRNA-155, and miRNA-210 biomarkers [ 78 ]. The dysregulation of miRNAs has been linked to the etiology of breast cancer, and studies have demonstrated that miRNAs expression profiles may be associated with tumor aggressiveness, treatment response, and patient prognosis in breast cancer [ 79 ].…”

Section: Biosensing Technologymentioning

confidence: 99%

Multifunctional carbon nanomaterials for diagnostic applications in infectious diseases and tumors

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

An electrochemical biosensor for simultaneous detection of breast cancer clinically related microRNAs based on a gold nanoparticles/graphene quantum dots/graphene oxide film

Abstract: An electrochemical biosensor employing a gold nanoparticles/graphene quantum dots/graphene oxide composite modified electrode is developed for the multiplex detection of miRNA breast cancer biomarkers.

Cited by 87 publications

References 65 publications

Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study

Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study

Review—Systematic Review on Electrochemical Biosensing of Breast Cancer miRNAs to Develop Alternative DCIS Diagnostic Tool

Multifunctional carbon nanomaterials for diagnostic applications in infectious diseases and tumors

Contact Info

Product

Resources

About